The firm was joined by fellow existing Medisse investor BioGeneration Ventures and newcomer IIG in the Series B round.
Medisse, which makes implants which are designed to disintegrate in the body, also received an innovation credit from the Dutch Ministry of Economic Affairs.
Company chairman Joost Holthuis, who represents BioGeneration Ventures on the Medisse board, said, “We are looking forward to bring a number of innovative resorbable products towards the clinic and first commercial use the coming years based on a proven and versatile technology platform.”
Crédit Agricole Private Equity changed its name to Omnes Capital following secondaries specialist Coller’s takeover of the unit in March 2012.
Although financial terms of the deal were not disclosed, the sale was said to be valued at just over €300m.
Coller has since sold the company back to the Omnes management team, but kept ownership of the portfolio of companies.
The new firm has €1.9bn of assets under management.
Copyright © 2013 AltAssets